v3.26.1
Fair Value Measurements - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 6 Months Ended 12 Months Ended
May 18, 2026
Jun. 12, 2025
May 31, 2026
Jun. 30, 2026
Dec. 31, 2025
Jan. 31, 2026
Jan. 29, 2026
Business Combination [Line Items]              
Fair value assets transfers out of level 3       $ 0 $ 0    
NDA acceptance under contingent consideration       $ 25,000      
Preferred stock, shares issued (in shares)       0 0    
Pre-Funded Warants [Member]              
Business Combination [Line Items]              
Warrants exercised           10,000 10,000
Issuance of common stock on exercise of pre funded warrants           9,989 9,989
Private Placement | Pre-Funded Warants [Member]              
Business Combination [Line Items]              
Warrants to purchase common stock (in USD per share)   $ 0.2          
Private Placement | Warrant [Member]              
Business Combination [Line Items]              
Exercise of Warrants   $ 10,400          
Warrants to purchase common stock (in USD per share)   $ 240          
Series C Preferred Stock              
Business Combination [Line Items]              
Exercise of Warrants     $ 11,000        
Specified Approval Milestones [Member]              
Business Combination [Line Items]              
Milestone Payment       $ 60,000      
Ery Del [Member]              
Business Combination [Line Items]              
Amount payable upon achievement of specified milestone.       5,000      
Milestone achievement related to market and sales       395,000      
Ery Del [Member] | Maximum              
Business Combination [Line Items]              
Maximum amount of future consideration payment       $ 485,000      
Orphai Therapeutics [Member]              
Business Combination [Line Items]              
Exercise of Warrants $ 72,000            
Financing Warrants to purchase stock 3,749,231            
Warrants to purchase common stock (in USD per share) $ 19.17     $ 19.17      
Warrants exercised       0      
Orphai Therapeutics [Member] | Common Stock [Member]              
Business Combination [Line Items]              
Convertible preferred stock, shares issued upon conversion 52            
Orphai Therapeutics [Member] | Warrant [Member]              
Business Combination [Line Items]              
Exercise of Warrants $ 11,000            
Warrants to purchase common stock (in USD per share)       $ 19.17      
Orphai Therapeutics [Member] | Private Placement              
Business Combination [Line Items]              
Exercise of Warrants 72,000            
Orphai Therapeutics [Member] | Private Placement | Warrant [Member]              
Business Combination [Line Items]              
Exercise of Warrants $ 72,000            
Orphai Therapeutics [Member] | Series C Preferred Stock              
Business Combination [Line Items]              
Preferred stock, shares issued (in shares) 72,100.322     10,964.505      
Convertible preferred stock, shares issued upon conversion       570,169      
Exercise price       $ 996.9      
Preferred stock price per share       19.17      
Financing Warrants to purchase stock 72,100.322            
Warrants to purchase common stock (in USD per share) $ 996.9     $ 996.9      
Orphai Therapeutics [Member] | Series C Preferred Stock | Common Stock [Member]              
Business Combination [Line Items]              
Convertible preferred stock, shares issued upon conversion 52            
Orphai Therapeutics [Member] | Series C Preferred Stock | Warrant [Member]              
Business Combination [Line Items]              
Preferred stock, shares issued (in shares) 83,064.827            
Orphai Therapeutics [Member] | Maximum | Series C Preferred Stock              
Business Combination [Line Items]              
Financing Warrants to purchase stock 72,100.322